425: Hyperliquid Strategies Files Form 425 on Sonnet BioTherapeutics
Business Combination Communication
Hyperliquid Strategies Inc. has filed a Form 425 communication regarding Sonnet BioTherapeutics Holdings, Inc. on November 18, 2025.
Summary
- Hyperliquid Strategies Inc. filed a Form 425.
- The filing is pursuant to Rule 425 under the Securities Act of 1933 and Rule 14a-12 under the Securities Exchange Act of 1934.
- Sonnet BioTherapeutics Holdings, Inc. is identified as the subject company.
- The Commission File No. for Sonnet BioTherapeutics Holdings, Inc. is 001-35570.
- The filing date is November 18, 2025.
Sentiment
Score: 5
Explanation: Neutral, as the filing is purely administrative and provides no substantive information beyond identifying the parties and the filing type.
Future Outlook
NA
Industry Context
NA
Key Dates
| Date | Description |
|---|---|
| November 18, 2025 | Date of Form 425 filing by Hyperliquid Strategies Inc. regarding Sonnet BioTherapeutics Holdings, Inc. |
Keywords
Hyperliquid Strategies, Sonnet BioTherapeutics, Form 425, SEC filing, Securities Act of 1933, Securities Exchange Act of 1934, business combination, merger communication
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.